Valneva SE Form 6-K Summary: Six Months Ended June 30, 2024
Business Context and Reporting Period
This Form 6-K reports the unaudited interim condensed consolidated financial statements and management report for Valneva SE for the six months ended June 30, 2024. Valneva is a specialty vaccine company developing and commercializing prophylactic vaccines for infectious diseases. The company markets three proprietary travel vaccines (IXIARO, DUKORAL, IXCHIQ) and maintains a pipeline including a Lyme disease vaccine (VLA15) partnered with Pfizer, a Shigella vaccine (S4V), and a Zika vaccine (VLA1601).
Key Financial Metrics
| Metric (€ million) | H1 2024 | H1 2023 |
|---|---|---|
| Total Revenues | 70.8 | 73.7 |
| Product Sales | 68.3 | 69.7 |
| Net Profit/(Loss) | 34.0 | (35.0) |
| Adjusted EBITDA | 56.2 | (28.3) |
| Cash and Cash Equivalents | 131.4 | 204.4 |
| Total Borrowings | 180.4 | 176.8 |
Revenue Breakdown: IXIARO sales increased 38% to €41.9 million (driven by U.S. military sales). DUKORAL sales decreased 13% to €14.9 million. IXCHIQ generated initial sales of €1.0 million. Third-party sales declined 37% to €10.5 million due to supply constraints.
Profitability: The net profit of €34.0 million was primarily driven by a one-time net gain of €90.8 million from the sale of a Priority Review Voucher (PRV). Excluding this gain, the company reported an operating loss.
Cash Flow: Net cash used in operating activities was €66.3 million. Net cash generated from investing activities was €87.6 million, largely due to PRV proceeds. Net cash used in financing activities was €16.6 million.
Material Changes vs. Prior Period
- Turnaround to Profit: The company shifted from a net loss of €35.0 million in H1 2023 to a net profit of €34.0 million in H1 2024, almost entirely attributable to the €90.8 million PRV sale gain.
- IXIARO Growth: Sales surged 38% year-over-year due to the resumption of regular supply patterns to the U.S. Department of Defense, which had minimal sales in H1 2023.
- Third-Party Decline: Third-party product sales dropped 37% due to supply shortages of distributed vaccines (Rabipur/RabAvert and Encepur).
- Debt Structure: In March 2024, the company amended its Deerfield and OrbiMed loan agreement to extend the interest-only period for the first $100 million tranche by 18 months, pushing principal repayments to January 2026.
- Expense Increases: R&D expenses rose to €29.7 million (from €26.0 million) due to manufacturing transfers and IXCHIQ development. Marketing expenses increased to €23.2 million (from €20.0 million) driven by IXCHIQ launch activities.
Guidance, Outlook, and Risks
2024 Full Year Guidance:
- Total Revenues: €170 million to €190 million.
- Product Sales: €160 million to €180 million.
- Other Income: €100 million to €110 million (reflecting the €95 million PRV proceeds).
- R&D Investments: €60 million to €75 million.
Operational Outlook:
- IXCHIQ: Expecting marketing authorizations in the UK and Brazil in H2 2024. First sales in Europe and Canada anticipated in Q4 2024. Label extension for adolescents expected in H2 2024.
- VLA15 (Lyme): Phase 3 VALOR trial primary vaccination series completed in July 2024. Trial completion expected by end of 2025, with regulatory submissions (BLA/MAA) targeted for 2026.
- S4V (Shigella): New partnership with LimmaTech Biologics announced August 1, 2024. Phase 2 trials expected to begin in H2 2024.
Risks and Contingencies:
- Regulatory Approval: Success of the Lyme vaccine depends on obtaining sufficient case counts in the Phase 3 trial. Delays in Brazilian approval for IXCHIQ could impact Phase 4 trials.
- Manufacturing: Supply shortages previously impacted IXIARO and DUKORAL. The company is transferring production to a new facility in Livingston, Scotland.
- Litigation: Ongoing legal proceedings regarding the 2013 merger with Intercell AG. A provision of €5.2 million has been recorded.
- Liquidity Covenants: The company must maintain a minimum liquidity of €35.0 million and a twelve-month rolling minimum revenue of €115.0 million under its loan agreement.
Investor Verification Checklist
- PRV Proceeds Utilization: Verify how the €95 million from the Priority Review Voucher sale is being allocated to R&D and debt reduction.
- IXCHIQ Commercialization: Monitor Q4 2024 sales performance in Europe and Canada and the timeline for UK/Brazil regulatory approvals.
- Lyme Vaccine Trial Data: Track the completion of the Phase 3 VALOR trial and the subsequent data readout expected in late 2025.
- Debt Covenants: Confirm continued compliance with the €35 million minimum liquidity and €115 million revenue covenants under the Deerfield/OrbiMed facility.
- Third-Party Wind-down: Assess the impact of the planned reduction of third-party sales to less than 5% of total revenue by 2026/2027 on overall gross margins.